Parkinson’s disease is a complex neurodegenerative disorder that can cause a number of debilitating motor and non-motor symptoms resulting from the death of nerve cells within the substantia nigra. With the emergence of the gut-brain axis, a scientific phenomenon that is predominantly influenced by the gut-microbiota, scientists continue to investigate whether Parkinson’s Disease may be treated through targeting the gut, not the brain.
Join this workshop to:
Natalia Palacios, Assistant Professor, UMass Lowell
Within the last ten years, translational microbiome research has accelerated dramatically and due to it’s dynamic nature, the microbiome has potential to serve as a diagnostic guide, determinant of treatment response, or even be re-engineered as a therapeutic intervention in itself.
However, the diversity of the ways in which the human microbiome can be successfully translated into products leads to a number of technical challenges with study design and associated analysis.
Through the exploration of insights across pharmaceutical product development, this unique workshop aims to review standard techniques for study design within translational microbiome studies to help inform a number of aspects within a discovery, pre-clinical and clinical setting. This will include perspectives on sample collection and storage, methodology for sample processing, data storage and interpretation, sequencing selection and clinical trial-design/execution.
Rita Colwell, Distinguished University Professor, University of Maryland
Rodolphe Clerval, Chief Business Officer, Enterome Bioscience
Alessio Fasano, Allan Walker Chair in Paediatric Gastroenterology & Nutrition, Massachusetts General Hospital
Recent research on the interactions between the gut microbiome, immune cell function and emerging immune checkpoint inhibitor therapies have begun to show the microbiome’s impact on immunotherapy response. Through the discussion of recent publications, this is a great opportunity to understand:
In this workshop, we will discuss the inter-individual variation of the microbiome and how this is applicable to future immuno-oncology research. The strengths and challenges of high-throughput sequencing of human clinical samples and mouse models of cancer will both be explored.
Lata Jayaramen, Head, Tumor Immunotherapy, Seres Therapeutics